Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7861.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8485 | |
MDA-MB-468 | TNBC | Basal A | AG1478 | EGFR | ErbB | 7905.016 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0810 | 0.0466 | 0.6240 | |
MDA-MB-415 | HR+ | Luminal | TCS PIM-1 1 | Pim kinase | PIM | 12333.135 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0098 | 0.0000 | 0.4305 | |
MDA-MB-436 | TNBC | Basal B | PD184352 | MEK | MAPK | 7898.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0820 | 0.0614 | 0.7130 | |
BT-20 | TNBC | Basal A | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5904.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6537 | |
Hs 578T | TNBC | Basal B | Sirolimus | MTOR | MTOR | 7474.069 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0115 | -0.0565 | 2.5606 | |
MX1 | Unknown | Unknown | PS-1145 | IKK | NFKB | 7523.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0407 | -9.0127 | 0.7668 | |
Hs 578T | TNBC | Basal B | Triciribine | AKT | AKT | 7472.074 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0523 | -0.0595 | 1.5922 | |
Hs 578T | TNBC | Basal B | GSK1838705A | IGF1R | RTK | 7475.091 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0020 | 0.1302 | 2.6839 | |
MCF7 | HR+ | Luminal | GW-5074 | CRAF | MAPK | 7493.088 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0387 | -2.8472 | 1.0513 | |
MDA-MB-436 | TNBC | Basal B | LY294002 | PI3K | PI3K | 7898.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7130 | |
Hs 578T | TNBC | Basal B | Triciribine | AKT | AKT | 7473.074 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0187 | -0.0877 | 2.5364 | |
Hs 578T | TNBC | Basal B | Methotrexate | DHFR | Metabolism | 7475.084 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0415 | -7.3003 | 2.7804 | |
MCF 10F | NM | - | Cetuximab | EGFR | ErbB | 7872.042 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0054 | -0.0002 | 1.3632 | |
HCC3153 | TNBC | Basal A | PS-1145 | IKK | NFKB | 7467.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0386 | -3.7264 | 1.2393 | |
HCC38 | TNBC | Basal B | Trametinib | MEK | MAPK | 9028.05 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0399 | -2.6337 | 0.9299 | |
HCC3153 | TNBC | Basal A | GW843682X | PLK | PLK | 10577.139 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0263 | -0.5932 | 0.9234 | |
MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 10077.026 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.3999 | |
EFM-192B | HER2amp | Luminal | Ribavirin | 15288.211 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0002 | -0.0013 | 0.9250 | |||
SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 10875.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0427 | -3.3446 | 0.7643 | |
MCF 10F | NM | - | FTase Inhibitor I | Ftase | MAPK | 12254.154 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0451 | -13.9008 | 1.6307 | |
MDA-MB-415 | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 7512.084 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0491 | -524.0720 | 0.7511 | |
HCC2185 | TNBC | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 9420.132 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0075 | -0.0001 | 0.3309 | ||
MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7884.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6074 | |
MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 9723.124 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0369 | -1.9688 | 0.9827 |